Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces New Study in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Related Questions
What is the expected timeline and scale for commercial uptake of the Decipher test in metastatic prostate cancer treatment protocols?
How does this breakthrough compare to competitor genomic tests and could it shift market share or reimbursement dynamics?
How will the positive Cell study results affect Veracyte's valuation and short-term stock momentum?